M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Belumosudil mesylate

First Posted Date: 2023-10-27

Last Posted Date: 2025-01-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 36

Registration Number: NCT06105554

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

Phase 1

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: ADI-PEG 20
Drug: Cabazitaxel
Drug: Carboplatin

First Posted Date: 2023-10-17

Last Posted Date: 2024-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT06085729

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers

Phase 2

Recruiting

Conditions: Metastatic Cancers
Fatigue

Interventions: Behavioral: Psychoeducational Intervention+Placebo
Behavioral: Psychoeducational Intervention
Drug: Open Label Placebo

First Posted Date: 2023-10-17

Last Posted Date: 2024-06-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 240

Registration Number: NCT06085716

Locations: 🇺🇸
MD Anderson Cancer Centerr, Houston, Texas, United States

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

Phase 1

Withdrawn

Conditions: Chronic Myelomonocytic Leukemia

Interventions: Drug: Azacitidine
Drug: Tamibarotene
Drug: Venetoclax

First Posted Date: 2023-10-17

Last Posted Date: 2024-03-07

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT06085638

A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

Phase 1

Recruiting

Conditions: Radical Prostatectomy
Prostate Cancer

Interventions: Drug: REGN5678
Drug: Piflufolastat F18

First Posted Date: 2023-10-17

Last Posted Date: 2024-07-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT06085664

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Randomized Control Trial for Patient Reported Outcomes and Safety in Outpatient Thyroid Lobectomy

Phase 2

Recruiting

Conditions: Thyroid Lobectomy

Interventions: Behavioral: Pre-Surgery Survey
Behavioral: Post-Surgery Surveys

First Posted Date: 2023-10-17

Last Posted Date: 2024-12-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 224

Registration Number: NCT06085625

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

Phase 2

Recruiting

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: Regorafenib

First Posted Date: 2023-10-17

Last Posted Date: 2025-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT06087263

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Phase 2

Recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Pembrolizumab
Drug: Bevacizumab
Drug: Cyclophosphamide

First Posted Date: 2023-10-16

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT06083844

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Minimally-invasive Stabilization of Pelvic Metastases With Photodynamic Nails: A Multi-center Prospective Study of Functional Outcome

Phase 1

Recruiting

Conditions: Pelvic Metastasis

First Posted Date: 2023-10-16

Last Posted Date: 2024-06-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT06083896

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Phase 1

Recruiting

Conditions: Myxoid/Round Cell Liposarcoma
Synovial Sarcoma

Interventions: Drug: Fludarabine phosphate
Drug: NY-ESO-1 TCR/IL-15 NK
Drug: Cyclophosphamide

First Posted Date: 2023-10-16

Last Posted Date: 2024-11-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 44

Registration Number: NCT06083883

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy